nach oben

European Journal of Nuclear Medicine and Molecular Imaging

01.05.2024 | Original Article

Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy

verfasst von: Tiancheng Li, Mimi Xu, Shuye Yang, Guolin Wang, Yinuo Liu, Kaifeng Liu, Kui Zhao, Xinhui Su

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Biochemical recurrence (BCR) following radical prostatectomy (RP) is a significant concern for patients with prostate cancer. Reliable prediction models are needed to identify patients at risk for BCR and facilitate appropriate management. This study aimed to develop and validate a clinical-radiomics model based on preoperative [18 F]PSMA-1007 PET for predicting BCR-free survival (BRFS) in patients who underwent RP for prostate cancer.

Materials and methods

A total of 236 patients with histologically confirmed prostate cancer who underwent RP were retrospectively analyzed. All patients had a preoperative [18 F]PSMA-1007 PET/CT scan. Radiomics features were extracted from the primary tumor region on PET images. A radiomics signature was developed using the least absolute shrinkage and selection operator (LASSO) Cox regression model. The performance of the radiomics signature in predicting BRFS was assessed using Harrell’s concordance index (C-index). The clinical-radiomics nomogram was constructed using the radiomics signature and clinical features. The model was externally validated in an independent cohort of 98 patients.

Results

The radiomics signature comprised three features and demonstrated a C-index of 0.76 (95% CI: 0.60–0.91) in the training cohort and 0.71 (95% CI: 0.63–0.79) in the validation cohort. The radiomics signature remained an independent predictor of BRFS in multivariable analysis (HR: 2.48, 95% CI: 1.47–4.17, p < 0.001). The clinical-radiomics nomogram significantly improved the prediction performance (C-index: 0.81, 95% CI: 0.66–0.95, p = 0.007) in the training cohort and (C-index: 0.78 95% CI: 0.63–0.89, p < 0.001) in the validation cohort.

Conclusion

We developed and validated a novel [18 F]PSMA-1007 PET-based clinical-radiomics model that can predict BRFS following RP in prostate cancer patients. This model may be useful in identifying patients with a higher risk of BCR, thus enabling personalized risk stratification and tailored management strategies.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Shao N, Wang Y, Jiang WY, Qiao D, Zhang SG, Wu Y, et al. Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer. Int J Cancer. 2013;133:1743–50. https://doi.org/10.1002/ijc.28162.CrossRefPubMed

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate Cancer. Eur Urol. 2017;71:630–42. https://doi.org/10.1016/j.eururo.2016.08.002.CrossRefPubMed

Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, et al. Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J. 2012;6:121–7. https://doi.org/10.5489/cuaj.11085.CrossRefPubMedPubMedCentral

Mesko S, Marks L, Ragab O, Patel S, Margolis DA, Demanes DJ, et al. Targeted prostate biopsy gleason score heterogeneity and implications for risk stratification. Am J Clin Oncol. 2018;41:497–501. https://doi.org/10.1097/COC.0000000000000308.CrossRefPubMedPubMedCentral

Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, et al. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:2354–63. https://doi.org/10.1158/1055-9965.EPI-13-0668.CrossRefPubMedPubMedCentral

Jones W, Griffiths K, Barata PC, Paller CJ. PSMA Theranostics: review of the current status of PSMA-Targeted imaging and Radioligand Therapy. Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12061367.

Mokoala K, Lawal I, Lengana T, Kgatle M, Giesel FL, Vorster M, et al. PSMA Theranostics: Sci Pract Cancers (Basel). 2021;13. https://doi.org/10.3390/cancers13153904.

Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, et al. (68)Ga-PSMA-11 PET/CT interobserver agreement for prostate Cancer assessments: an International Multicenter prospective study. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2017;58:1617–23. https://doi.org/10.2967/jnumed.117.190827.CrossRef

10.

Duan H, Baratto L, Hatami N, Liang T, Mari Aparici C, Davidzon GA, et al. 68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: influence of dual-time and PMT- vs SiPM-based detectors. Translational Oncol. 2022;15:101293. https://doi.org/10.1016/j.tranon.2021.101293.CrossRef

11.

Mattiolli AB, Santos A, Vicente A, Queiroz M, Bastos D, Herchenhorn D, et al. Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study. Int Braz J Urol. 2018;44:892–9. https://doi.org/10.1590/S1677-5538.IBJU.2017.0632.CrossRefPubMedPubMedCentral

12.

Dekalo S, Kuten J, Mintz I, Fahoum I, Gitstein G, Keizman D, et al. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection. Prostate Cancer Prostatic Dis. 2021;24:910–6. https://doi.org/10.1038/s41391-021-00347-y.CrossRefPubMed

13.

Draulans C, De Roover R, van der Heide UA, Kerkmeijer L, Smeenk RJ, Pos F, et al. Optimal (68)Ga-PSMA and (18)F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:1211–8. https://doi.org/10.1007/s00259-020-05059-4.CrossRefPubMed

14.

Hong JJ, Liu BL, Wang ZQ, Tang K, Ji XW, Yin WW, et al. The value of (18)F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer. EJNMMI Res. 2020;10:138. https://doi.org/10.1186/s13550-020-00730-1.CrossRefPubMedPubMedCentral

15.

Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of (18)F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate Cancer after Radical Prostatectomy. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2019;60:362–8. https://doi.org/10.2967/jnumed.118.212233.CrossRef

16.

Zhou X, Jiang X, Liu L, Wang X, Li C, Yao Y, et al. Evaluation of (18)F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. Transl Oncol. 2022;15:101292. https://doi.org/10.1016/j.tranon.2021.101292.CrossRefPubMed

17.

Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62. https://doi.org/10.1038/nrclinonc.2017.141.CrossRefPubMed

18.

Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563–77. https://doi.org/10.1148/radiol.2015151169.CrossRefPubMed

19.

Xue XQ, Yu WJ, Shi X, Shao XL, Wang YT. (18)F-FDG PET/CT-based radiomics nomogram for the preoperative prediction of lymph node metastasis in gastric cancer. Front Oncol. 2022;12:911168. https://doi.org/10.3389/fonc.2022.911168.CrossRefPubMedPubMedCentral

20.

Wang L, Li T, Hong J, Zhang M, Ouyang M, Zheng X, et al. (18)F-FDG PET-based radiomics model for predicting occult lymph node metastasis in clinical N0 solid lung adenocarcinoma. Quant Imaging Med Surg. 2021;11:215–25. https://doi.org/10.21037/qims-20-337.CrossRefPubMedPubMedCentral

21.

Xue B, Wu S, Zhang M, Hong J, Liu B, Xu N, et al. A radiomic-based model of different contrast-enhanced CT phase for differentiate intrahepatic cholangiocarcinoma from inflammatory mass with hepatolithiasis. Abdom Radiol (NY). 2021;46:3835–44. https://doi.org/10.1007/s00261-021-03027-6.CrossRefPubMed

22.

Cardinale J, Martin R, Remde Y, Schafer M, Hienzsch A, Hubner S, et al. Procedures for the GMP-Compliant production and Quality Control of [(18)F]PSMA-1007: a Next Generation Radiofluorinated Tracer for the detection of prostate Cancer. Pharmaceuticals (Basel). 2017;10. https://doi.org/10.3390/ph10040077.

23.

Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62. https://doi.org/10.1016/j.eururo.2020.09.042.CrossRefPubMed

24.

Mazzone E, Gandaglia G, Ploussard G, Marra G, Valerio M, Campi R, et al. Risk stratification of patients candidate to Radical Prostatectomy based on clinical and multiparametric magnetic resonance imaging parameters: Development and External Validation of Novel Risk groups. Eur Urol. 2022;81:193–203. https://doi.org/10.1016/j.eururo.2021.07.027.CrossRefPubMed

25.

Roberts MJ, Morton A, Papa N, Franklin A, Raveenthiran S, Yaxley WJ, et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2022;49:3289–94. https://doi.org/10.1007/s00259-022-05756-2.CrossRefPubMedPubMedCentral

26.

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P et al. Radiomics: extracting more information from medical images using advanced feature analysis. European journal of cancer (Oxford, England: 1990). 2012;48:441-6. https://doi.org/10.1016/j.ejca.2011.11.036.

27.

Jia TY, Xiong JF, Li XY, Yu W, Xu ZY, Cai XW, et al. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. Eur Radiol. 2019;29:4742–50. https://doi.org/10.1007/s00330-019-06024-y.CrossRefPubMed

28.

Thawani R, McLane M, Beig N, Ghose S, Prasanna P, Velcheti V, et al. Radiomics and radiogenomics in lung cancer: a review for the clinician. Lung Cancer. 2018;115:34–41. https://doi.org/10.1016/j.lungcan.2017.10.015.CrossRefPubMed

29.

Lee G, Lee HY, Park H, Schiebler ML, van Beek EJR, Ohno Y, et al. Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: state of the art. Eur J Radiol. 2017;86:297–307. https://doi.org/10.1016/j.ejrad.2016.09.005.CrossRefPubMed

30.

Feng ST, Jia Y, Liao B, Huang B, Zhou Q, Li X, et al. Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. Eur Radiol. 2019;29:4648–59. https://doi.org/10.1007/s00330-018-5935-8.CrossRefPubMed

31.

Li H, Mendel KR, Lan L, Sheth D, Giger ML. Digital mammography in breast Cancer: Additive Value of Radiomics of breast parenchyma. Radiology. 2019;291:15–20. https://doi.org/10.1148/radiol.2019181113.CrossRefPubMed

32.

Zang S, Ai S, Yang R, Zhang P, Wu W, Zhao Z, et al. Development and validation of (68)Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer. EJNMMI Res. 2022;12:63. https://doi.org/10.1186/s13550-022-00936-5.CrossRefPubMedPubMedCentral

33.

Spohn SKB, Schmidt-Hegemann NS, Ruf J, Mix M, Benndorf M, Bamberg F, et al. Development of PSMA-PET-guided CT-based radiomics signature to predict biochemical recurrence after salvage radiotherapy. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06195-3.CrossRefPubMedPubMedCentral

34.

Chen A, Lu L, Pu X, Yu T, Yang H, Schwartz LH, et al. CT-Based Radiomics Model for Predicting Brain Metastasis in Category T1 lung adenocarcinoma. AJR Am J Roentgenol. 2019;213:134–9. https://doi.org/10.2214/AJR.18.20591.CrossRefPubMed

35.

Ji GW, Zhu FP, Zhang YD, Liu XS, Wu FY, Wang K, et al. A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma. Eur Radiol. 2019;29:3725–35. https://doi.org/10.1007/s00330-019-06142-7.CrossRefPubMed

36.

Tan Y, Zhang ST, Wei JW, Dong D, Wang XC, Yang GQ, et al. A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery. Eur Radiol. 2019;29:3325–37. https://doi.org/10.1007/s00330-019-06056-4.CrossRefPubMed

37.

Zhang R, Xu L, Wen X, Zhang J, Yang P, Zhang L, et al. A nomogram based on bi-regional radiomics features from multimodal magnetic resonance imaging for preoperative prediction of microvascular invasion in hepatocellular carcinoma. Quant Imaging Med Surg. 2019;9:1503–15. https://doi.org/10.21037/qims.2019.09.07.CrossRefPubMedPubMedCentral

38.

Tsurumaki Sato Y, Fukuhara H, Suzuki M, Fujimura T, Nakagawa T, Nishimatsu H, et al. Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer. BMC Urol. 2014;14:13. https://doi.org/10.1186/1471-2490-14-13.CrossRefPubMed

Titel: Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy
verfasst von: Tiancheng Li
Mimi Xu
Shuye Yang
Guolin Wang
Yinuo Liu
Kaifeng Liu
Kui Zhao
Xinhui Su
Publikationsdatum: 01.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06734-6

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy

Abstract

Purpose

Materials and methods

Results

Conclusion

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten